Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2026 | Sequential versus combination BR-BTKi therapy in MCL: which patients may benefit most

Yucai Wang • 10 Sep 2026
SOHO 2026
Mantle Cell Lymphoma Acalabrutinib Bendamustine BTK inhibitors Ibrutinib Rituximab
ECHO SHINE

Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discusses sequential first-line bendamustine-rituximab (BR) followed by second-line BTK inhibitor therapy in mantle cell lymphoma (MCL), suggesting it may achieve progression-free survival rates similar to upfront BR-BTKi combination therapy. He notes that a sequential approach may be reasonable for low-risk patients, while upfront combination therapy may better suit those with high-risk features. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yucai Wang

Balancing efficacy and toxicity risks when combining BTK and BCL2 inhibitors in patients with MCL
1:44
Balancing efficacy and toxicity risks when combining BTK and BCL2 inhibitors in patients with MCL
Yucai Wang • 10 Sep 2026
Challenges that remain in treating older patients with MCL & the value of tailored approaches
2:31
Challenges that remain in treating older patients with MCL & the value of tailored approaches
Yucai Wang • 18 Jun 2025
A Phase I/II trial of orelabrutinib, a covalent BTK inhibitor, in R/R MCL
3:23
A Phase I/II trial of orelabrutinib, a covalent BTK inhibitor, in R/R MCL
Yucai Wang • 18 Jun 2025
Rapid ramp-up dosing of bispecific antibodies targeting CD3 and CD20 for R/R LBCL
4:07
Rapid ramp-up dosing of bispecific antibodies targeting CD3 and CD20 for R/R LBCL
Yucai Wang • 18 Jun 2025

Related Videos

Relapse patterns and sequencing of CD19 CAR T-cell therapies in MCL: lessons from DLBCL and beyond
1:14
Relapse patterns and sequencing of CD19 CAR T-cell therapies in MCL: lessons from DLBCL and beyond
Elise Chong • 10 Sep 2026
Promising first real-world CIBMTR data for liso-cel in R/R mantle cell lymphoma
0:58
Promising first real-world CIBMTR data for liso-cel in R/R mantle cell lymphoma
Elise Chong • 10 Sep 2026
Balancing efficacy and toxicity risks when combining BTK and BCL2 inhibitors in patients with MCL
1:44
Balancing efficacy and toxicity risks when combining BTK and BCL2 inhibitors in patients with MCL
Yucai Wang • 10 Sep 2026
Sequencing covalent and non-covalent BTK inhibitors in MCL
0:57
Sequencing covalent and non-covalent BTK inhibitors in MCL
Nirav Niranjan Shah • 13 Jun 2026
The content of VJHemOnc is intended for healthcare professionals